Zimmer Biomet Holdings, Inc. reported fourth‑quarter 2025 revenue of $2.244 billion, a 10.9% year‑over‑year increase and 9.2% on a constant‑currency basis. The lift was driven by strong demand for hip and knee implants in the United States and a rebound in the EMEA region, offsetting modest growth in the Asia‑Pacific market.
Adjusted earnings per share reached $2.42, beating consensus estimates of $2.38–$2.40 by $0.02–$0.04, or 0.9–1.7%. The beat was largely attributable to disciplined cost management, a favorable product mix that favored higher‑margin knee implants, and the continued momentum of the company’s “Magnificent Seven” product line. The company’s operating margin contracted slightly to 29.1% from 30.2% in the prior year, reflecting increased commercial investment and the integration of the Paragon 28 acquisition.
Segment‑level data show U.S. hip sales grew 7.9% to $1.12 billion, U.S. knee sales rose 6.0% to $1.07 billion, and international hip and knee sales increased 5.6% and 12.1% respectively. The S.E.T. category posted a 20.1% jump to $0.18 billion, while the Technology & Data segment grew 8.3% to $0.12 billion. Compared with Q4 2024, revenue rose from $2.023 billion and adjusted EPS from $2.31 to $2.42, indicating a 5.1% YoY EPS gain.
Management guided for full‑year 2026 adjusted diluted EPS of $8.30–$8.45, slightly below the consensus estimate of $8.48. The company also reaffirmed its revenue guidance of $2.20–$2.22 billion for the year, a modest increase from the prior estimate of $2.18 billion. The tempered outlook reflects the planned U.S. sales‑force transformation and ongoing integration of acquisitions, which are expected to create short‑term headwinds but support long‑term growth.
Chief Executive Officer Ivan Tornos highlighted that the quarter “demonstrated strong execution and resilience amid tariff headwinds and integration costs.” Chief Financial Officer Suketu Upadhyay noted that the company’s “adjusted earnings per share of $2.42, up 4.8% YoY, were driven by robust demand for key products and disciplined cost control.” The market reaction was positive, with analysts citing the earnings beat and solid segment performance as key drivers, while the cautious 2026 guidance tempered enthusiasm.
Overall, Zimmer Biomet’s Q4 2025 results underscore a solid operational foundation, a favorable product mix, and disciplined cost management. The company’s guidance signals confidence in maintaining profitability, even as it navigates strategic investments and integration efforts that may moderate near‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.